Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL
July 15th 2024
Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.